1 Introduction 7

• 1.1 Industry Definition and Research Scope 7
  • 1.1.1 Industry Definition 7
  • 1.1.2 Research Scope 8
• 1.2 Research Methodology 10
  • 1.2.1 Overview of Market Research Methodology 10
  • 1.2.2 Market Assumption 11
  • 1.2.3 Secondary Data 11
  • 1.2.4 Primary Data 11
  • 1.2.5 Data Filtration and Model Design 12
  • 1.2.6 Market Size/Share Estimation 13
  • 1.2.7 Research Limitations 14
• 1.3 Executive Summary 15

2 Market Overview and Dynamics 17

• 2.1 Market Size and Forecast 17
• 2.2 Major Growth Drivers 18
• 2.3 Market Restraints and Challenges 21
• 2.4 Emerging Opportunities and Market Trends 24
• 2.5 Porter’s Fiver Forces Analysis 27

3 Segmentation of Asia-Pacific Market by Product Type 31

• 3.1 Market Overview by Product Type 31
• 3.2 Human Insulin Drugs 33
• 3.3 Human Insulin Delivery Devices 34

4 Segmentation of Asia-Pacific Human Insulin Drugs Market by Drug Product 35

• 4.1 Market Overview by Drug Product 35
• 4.2 Modern Human Insulin 37
  • 4.2.1 Modern Human Insulin by Type 39
  • 4.2.2 Modern Human Insulin by Brand 42
• 4.3 Traditional Human Insulin 49
  • 4.3.1 Traditional Human Insulin by Type 51
  • 4.3.2 Traditional Human Insulin by Brand 54

5 Segmentation of Asia-Pacific Human Insulin Delivery Devices Market by Device Product 57

• 5.1 Market Overview by Product 57
• 5.2 Syringes 59
• 5.3 Pens 60
• 5.4 Pumps 61
• 5.5 Other Devices 63

6 Segmentation of Asia-Pacific Market by Application 64

• 6.1 Market Overview by Application 64
• 6.2 Type 1 Diabetes 66
• 6.3 Type 2 Diabetes 67
• 6.4 Gestational Diabetes and Prediabetes 68

7 Segmentation of Asia-Pacific Market by Distribution Channel 69

• 7.1 Market Overview by Distribution Channel 69
• 7.2 Hospital Pharmacies 71
• 7.3 Retail Pharmacies 72
• 7.4 Online Pharmacies 73

8 Asia-Pacific Market 2019-2026 by Country 74

• 8.1 Overview of Asia-Pacific Market 74
• 8.2 Japan 77
• 8.3 China 80
• 8.4 Australia 82
• 8.5 India 84
• 8.6 South Korea 86
• 8.7 Rest of APAC Region 88

9 Competitive Landscape 90

• 9.1 Overview of Key Vendors 90
• 9.2 New Product Launch, Partnership, Investment, and M&A 94
• 9.3 Company Profiles 96

Astra Zeneca PLC 96

Biocon 98

Eli Lilly 99

Exir 100

Julphar 101

Novo Nordisk AS 102

Pfizer 103

Sanofi Aventis 104

Sedico 105

Wockhardt 106

10 Investing in Asia-Pacific Market: Risk Assessment and Management 107

• 10.1 Risk Evaluation of Asia-Pacific Market 107
• 10.2 Critical Success Factors (CSFs) 110

Related Reports and Products 113

Asia Pacific human insulin market will grow by 9.74% annually over forecast years with a total addressable market cap of $66.02 billion for 2020-2026.
Highlighted with 37 tables and 56 figures, this 113-page report “Asia Pacific Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify Asia Pacific human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country.
Based on product type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Human Insulin Drugs
• Human Insulin Delivery Devices
Based on product, the Asia Pacific Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand)
• Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand)
Based on product, the Asia Pacific Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Syringes
• Pens (further segmented into Disposable, Reusable, Pen needles)
• Pumps
• Others
Based on application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes and Prediabetes
Based on distribution channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific human insulin market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players:
Astra Zeneca PLC
Biocon
Eli Lilly
Exir
Julphar
Novo Nordisk AS
Pfizer
Sanofi Aventis
Sedico
Wockhardt
(Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)